
Global law firm Goodwin announced that Kirkie Maswoswe joined the firm’s Mergers & Acquisitions practice and Technology group as a partner, resident in the New York office.
“Kirkie has a strong mix of business and legal acumen in public M&A between her time in private practice and as an investment banker, bringing an invaluable perspective to advising our clients,” said Lisa Haddad, co-chair of Goodwin’s Public M&A and Corporate Governance practice. “The number, size, and complexity of our public M&A transactions have materially increased over the past decade. We expect this trend to continue and are thrilled to have Kirkie playing a significant role in our clients’ success.”
Maswoswe focuses her practice on mergers and acquisitions, shareholder activism defense, financial advisory representations, corporate governance, and general corporate matters. She has broad experience across various industries. In addition to a number of years at international law firms, Maswoswe previously served as an investment banker at a leading global investment bank, where she advised clients in the technology sector.
Goodwin has been named the number one firm (by deal count) for global M&A by Refinitiv in its league tables for Q3 2022. The firm’s recent public M&A transactions include Citrix Systems’ $16.5 billion sale to affiliates of Vista Equity Partners and Evergreen Coast Capital; SailPoint’s $6.9 billion acquisition by Thoma Bravo; Mimecast’s $5.8 billion sale to funds advised by Permira; Trillium Therapeutics’ $2.2 billion sale to Pfizer; Retail Properties of America’s $7.5 billion merger with Kite Realty Group Trust; and MyoKardia’s $13.1 billion sale to Bristol Myers Squibb.
Featured News
Federal Reserve Greenlights Capital One’s $35.3 Billion Acquisition of Discover
Apr 18, 2025 by
CPI
Google to Appeal Partial Ruling in DOJ Antitrust Case
Apr 18, 2025 by
CPI
Indian Ad Agencies Warned Against WhatsApp Discussions After Antitrust Raids
Apr 17, 2025 by
CPI
US Court Ruling Against Google Spurs Fresh Antitrust Tensions in Europe
Apr 17, 2025 by
CPI
AstraZeneca Accused of Stifling Biosimilar Competition for Rare Disease Drug
Apr 17, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – The Airline Industry
Apr 10, 2025 by
CPI
Boosting Competition in International Aviation
Apr 10, 2025 by
Jeffrey N. Shane
Reshaping Competition Policy for the U.S. Airline Industry
Apr 10, 2025 by
Diana L. Moss
Algorithmic Collusion in the Skies: The Role of AI in Shaping Airline Competition
Apr 10, 2025 by
Qi Ge, Myongjin Kim & Nicholas Rupp
Competition in U.S. Airline Markets: Major Developments and Economic Insights
Apr 10, 2025 by
Germán Bet